Dermatol. praxi. 2019;13(1):21-24 | DOI: 10.36290/der.2019.004

Urticaria – review of disease and treatment, new antihistamine bilastin

MUDr. Jarmila Čelakovská, Ph.D.
Klinika nemocí kožních a pohlavních FN a LF UK Hradec Králové

The aim of this article is to summarize the current knowledge about urticaria. This artile gives the review about the therapy with
antihistamins, about their pharmacology and the proven efficacy and safety profile of bilastine, high selective antihistaminic
treatment for H1 receptors in the management of urticaria.

Keywords: urticaria, treatment of urticaria, antihistamins, bilastin

Published: March 21, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Čelakovská J. Urticaria – review of disease and treatment, new antihistamine bilastin. Dermatol. praxi. 2019;13(1):21-24. doi: 10.36290/der.2019.004.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Pawankar R, Canonica GW, Holgate ST, Lockey RF, Blaiss MS. WAO White Book on Allergy: Update 2013. Milwaukee, WI: World Allergy Organization; 2013.
    2. Kumar Y, Bhatia A. Immunopathogenesis of allergic disorders: current concepts. Expert Rev Clin Immunol 2013; 9: 211-226. Go to original source... Go to PubMed...
    3. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Global Allergy and Asthma European Network. Grading of Recommendations Assessment, Development and Evaluation Working Group Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010; 126: 466-476. Go to original source... Go to PubMed...
    4. Zuberbier T, Aberer W, Asero R, et al. European Academy of Allergy and Clinical Immunology. Global Allergy and Asthma European Network. European Dermatology Forum. World Allergy Organization The EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014; 69: 868-887. Go to original source... Go to PubMed...
    5. Church DS, Church MK. Pharmacology of antihistamines. World Allergy Organ J. 2011; 4(3 suppl): S22-S27. Go to original source... Go to PubMed...
    6. Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A, Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy. 2011; 66: 317-330. Go to original source... Go to PubMed...
    7. Zuberbier T. Urticaria. Allergy 2003; 58: 1224-1234. Go to original source... Go to PubMed...
    8. Ferrer M, Sastre J, Jauregui I, et al. Effect of antihistamine up-dosing in chronic urticaria. J Investig Allergol Clin Immunol 2011; 21(suppl 3): 34-39.
    9. Muller BA. Urticaria and angioedema: a practical approach. Am Fam Physician 2004; 69: 1123-1128. Go to PubMed...
    10. Sanchez-Borges M, Ansotegui I, Jimenez JM, Rojo MI, Serrano C, Ya?ez A. Comparative efficacy of non-sedating antihistamine updosing in patients with chronic urticaria. World Allergy Organ J 2014; 7: 33. Go to original source... Go to PubMed...
    11. Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report. Allergy 2011; 66: 317-330. Go to original source... Go to PubMed...
    12. Zuberbier T, Balke M, Worm M, Edenharter G, Maurer M. Epidemiology of urticaria: a representative cross-sectional population survey. Clin Exp Dermatol 2010; 35: 869-873. Go to original source... Go to PubMed...
    13. Staevska M, Gugutkova M, Lazarova C, et al. Night-time sedating H1-antihistamine increases daytime somnolence but not treatment efficacy in chronic spontaneous urticaria: a randomized controlled trial. Br J Dermatol 2014; 171: 148-154. Go to original source... Go to PubMed...
    14. Grattan CEH, Humphreys F. Guidelines for evaluation and management of urticaria in adults and children. Br J Dermatol. 2007; 157: 1116-1123. Go to original source... Go to PubMed...
    15. Baiardini I, Giardini A, Pasquali M, et al. Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy. Allergy 2003; 58: 621-623. Go to original source... Go to PubMed...
    16. Staubach P, Dechene M, Metz M, et al. High prevalence of mental disorders and emotional distress in patients with chronic spontaneous urticaria. Acta Derm Venereol. 2011; 91: 557-561. Go to original source... Go to PubMed...
    17. Zazzali JL, Broder MS, Chang E, Chiu MW, Hogan DJ. Cost, utilization, and patterns of medication use associated with chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2012; 108: 98-102. Go to original source... Go to PubMed...
    18. Mahdy AM, Webster NR. Histamine and antihistamines. Anaesth Intensive Care Med 2014; 15: 5. Go to original source...
    19. Bousquet J, Ansotegui I, Canonica GW, et al. Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review. Curr Med Res Opin 2012; 28: 131-139. Go to original source... Go to PubMed...
    20. Ridolo E, Montagni M, Bonzano L, Incorvaia C, Canonica GW. Bilastine: new insight into antihistamine treatment. Clin Mol Allergy 2015; 13: 1. Go to original source... Go to PubMed...
    21. Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol 2011; 128: 1139-1150. Go to original source... Go to PubMed...
    22. Church MK. Safety and efficacy of bilastine: a new H(1)-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Expert Opin Drug Saf. 2011; 10: 779-793. Go to original source... Go to PubMed...
    23. Estelle F, Simons R. H1-receptor antagonists: safety issues. Ann Allergy Asthma Immunol 1999; 83: 481-488. Go to original source... Go to PubMed...
    24. Corcostegui R, Labeaga L, Innerarity A, Berisa A, Orjales A. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs R D. 2005; 6: 371-384. Go to original source... Go to PubMed...
    25. Jauregizar N, de la Fuente L, Lucero ML, Sologuren A, Leal N, Rodríguez M. Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine. Clin Pharmacokinet 2009; 48: 543-554. Go to original source... Go to PubMed...
    26. Sadaba B, Gomez-Guiu A, Azanza JR, Ortega I, Valiente R. Oral availability of bilastine. Clin Drug Investig 2013; 33: 375-381. Go to original source... Go to PubMed...
    27. Lucero ML, Gonzalo A, Ganza A, et al. Interactions of bilastine, a new oral H(1) antihistamine, with human transporter systems. Drug Chem Toxicol 2012; 35(suppl 1): 8-17. Go to original source... Go to PubMed...
    28. Horak F, Zieglmayer P, Zieglmayer R, Lemell P. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm Res 2010; 59: 391-398. Go to original source... Go to PubMed...
    29. Zuberbier T, Oanta A, Bogacka E, et al. Bilastine International Working Group Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy 2010;65:516-528. Go to original source... Go to PubMed...
    30. Church MK. Comparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare responses in humans. Inflamm Res 2011; 60: 1107-1112. Go to original source... Go to PubMed...
    31. Kulthanan K, Jiamton S, Thumpimukvatana N, Pinkaew S. Chronic idiopathic urticaria: prevalence and clinical course. J Dermatol 2007; 34: 294-301. Go to original source... Go to PubMed...
    32. Meltzer EO, Blaiss MS, Naclerio RM, et al. Burden of allergic rhinitis: allergies in America, Latin America, and Asia-Pacific adult surveys. Allergy Asthma Proc 2012;33(suppl 1):S113-S141. Go to original source... Go to PubMed...
    33. Krause K, Spohr A, Zuberbier T, Church MK, Maurer M. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy 2013; 68: 921-928. Go to original source... Go to PubMed...
    34. Garcia-Gea C, Martinez J, Ballester MR, Gich I, Valiente R, Antonijoan RM. Psychomotor and subjective effects of bilastine, hydroxyzine, and cetirizine, in combination with alcohol: a randomized, double-blind, crossover, and positive-controlled and placebo-controlled phase I clinical trials. Hum Psychopharmacol 2014; 29: 120-132. Go to original source... Go to PubMed...
    35. Conen S, Theunissen EL, Van Oers AC, Valiente R, Ramaekers JG. Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers. J Psychopharmacol 2011; 25: 1517-1523. Go to original source... Go to PubMed...
    36. Yanai K, Ryu JH, Watanabe T, et al. Histamine H1 receptor occupancy in human brains after single oral doses of histamine H1 antagonists measured by positron emission tomography. Br J Pharmacol 1995; 116: 1649-1655. Go to original source... Go to PubMed...
    37. Graff C, Struijk JJ, Kanters JK, Andersen MP, Toft E, Tyl B. Effects of bilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study. Clin Drug Investig 2012; 32: 339-351. Go to original source... Go to PubMed...

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.